Trial Profile
Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BEVERLY; BEVERLY1
- Sponsors UNICANCER
- 18 Oct 2019 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 04 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.